| [Clostridium] scindens| ATCC 35704| CIP 106687| Clostridium scindens| Clostridium scindens Morris et al. 1985| DSM 5676| Eubacterium sp. (strain VPI 12708)| Eubacterium sp. VPI 12708| Eubacterium sp. VPI-12708| Eubacterium VPI-12708| JCM 6567| strain Bokkenheuser 19
Bile Acid Metabolism: Clostridium scindens plays a role in bile acid metabolism in the gut. It has the ability to convert primary bile acids, which are produced by the liver, into secondary bile acids through a process known as dehydroxylation. This metabolic activity can influence the composition of bile acids in the digestive system.
Impact on Host Metabolism: The metabolism of bile acids by Clostridium scindens has been linked to various physiological effects. Secondary bile acids, produced by the action of this bacterium, may have implications for host metabolism, lipid absorption, and energy balance. They can also interact with host receptors, influencing signaling pathways related to metabolism.
Influence on Inflammation and Immunity: Some studies suggest that the activities of Clostridium scindens in bile acid metabolism may have implications for inflammation and immune responses. The modulation of bile acid composition in the gut can influence the gut environment and potentially impact the host's immune system.
Potential Therapeutic Applications: Given its role in bile acid metabolism and potential effects on host health, Clostridium scindens has been explored for therapeutic applications. Research has investigated the use of this bacterium or its metabolites in the context of certain diseases, including metabolic disorders and inflammatory conditions.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | UD-Low | UD-High | KM Low | KM High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High | KM Percentile Low | KM Percentile High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Labs | 3.18 | 0 | 0 | 1 | 28310 | 0 | 14938 | 3237.9 | 727 | 5969.3 | 0 | 4746 | 0 %ile | 100 %ile |
thorne | 100 | 311 | 2763 | 49 | 1830 | 939.2 | 836 | 454.4 | 616 | 968 | 0 %ile | 100 %ile | ||
thryve | 77.98 | 0 | 177 | 26 | 478 | 0 | 5242 | 597.9 | 96 | 2369.4 | 0 | 480 | 12.1 %ile | 90.3 %ile |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|---|---|---|---|
Thorne (20/80%ile) | 0 | 1.85 | 0 | 0.0002 |
XenoGene | 0 | 5000 | 0 | 0.5 |
GanzImmun Diagostics | 10 | 990000 | 0.001 | 99 |
Medivere | 100 | 990000 | 0.01 | 99 |
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
BiomeSightRdp | 25 % | 0.017 % | 0.008 % | 8.0 | 32 |
bugspeak | 100 % | 0.02 % | % | 1.0 | 1 |
CerbaLab | 100 % | 0.491 % | 0.401 % | 3.0 | 3 |
CosmosId | 43.75 % | 0.229 % | 0.75 % | 14.0 | 32 |
custom | 50.847 % | 0.761 % | 0.801 % | 30.0 | 59 |
es-xenogene | 75.862 % | 0.313 % | 0.414 % | 22.0 | 29 |
GanzimmunDiag | 100 % | 0.048 % | 0 % | 3.0 | 3 |
Medivere | 42.857 % | 0.003 % | 0.002 % | 3.0 | 7 |
Microba | 17.857 % | 0.097 % | 0.118 % | 5.0 | 28 |
Microba1 | 100 % | 0.89 % | % | 1.0 | 1 |
SequentiaBiotech | 5.556 % | 0.036 % | 0.012 % | 2.0 | 36 |
Thorne | 85.556 % | 0.092 % | 0.078 % | 77.0 | 90 |
Thryve | 79.031 % | 0.061 % | 0.221 % | 1093.0 | 1383 |
Click on Impact for information if high or low levels are causing the impact
Magnitude | Impact | Symptom |
---|
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.